This Cannabinoid Focused Biotech Company Just Made Major Progress In Mexico

Mexico is one of the most excited emerging international cannabis markets and is an opportunity that we have been highly focused on. 

Mexico’s legislation to legalize recreational cannabis has hit a snag and it may take a few months longer than expected for it to pass. We believe Mexico’s recreational cannabis market will open and it is a matter of when, not if. 

Earlier this week, Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a penny stock cannabis company, reported to have received Notice of Allowance from the Mexican Patent and Trademark Office (IMPI) in relation to its patent for a system and method for high throughput screening of cancer cells.

The granting of the notice from Mexico’s patent authority comes after the European Patent Office (EPO) issued an Intention to Grant a European Patent notice to the company in October 2020. The notice that was issued from Europe’s patent office covering the same application that was filed in Mexico. 

Download our free report on this emerging cannabinoid biotech leader

Although we have been following Cannabics from the sidelines, the patent has already been granted in Israel and South Africa. These approvals are a testament to the company’s innovative and novel approach to the drug discovery process and we will monitor how the story advances from here

As it relates to the Mexican cannabis market, we prefer operators like Canopy Growth Corporation (WEED.TO) (CGC), Aurora Cannabis Inc. (ACB.TO) (ACB), and Khiron Life Sciences Corporation (KHRN.V) (KHRNF). While the patent that Cannabics has been focused on is significant, the company needs more resources to execute on its growth strategy and we will continue to closely follow how the Mexican cannabis market evolves from here.

If you are interested in learning more about the Mexican cannabis market, please send an email to support@technical420.com with the subject “Mexican Cannabis Market” to be added to our distribution list. 

For the fastest access to data on the Mexican cannabis market, you can sign up for our free newsletter!

Pursuant to an agreement between StoneBridge Partners LLC and Cannabics Pharmaceuticals Inc. (CNBX) we have been hired for a period of 30 days beginning June 7, 2021 and ending July 7, 2021 to publicly disseminate information about (CNBX) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month (CBNX) for or were paid “0” shares of restricted common shares. We own zero shares of (CNBX), which we purchased in the open market. We plan to sell the “ZERO” shares of (CNBX) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CNBX) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Top Stories